Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 3/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262370 | 1.00 | MME (0.56) | MMESLC1A3SLC1A2CPA1CACNA2D1 | |
| SCHEMBL5870523 | 1.00 | MME (0.56) | MMESLC1A3SLC1A2CPA1CACNA2D1 | |
| SCHEMBL14591440 | 0.87 | FOLH1 (0.62) | MMECPA1FOLH1ADRA1ACPB1 | |
| SCHEMBL524140 | 0.87 | FOLH1 (0.62) | MMECPA1FOLH1ADRA1ACPB1 | |
| Hydrochloric Acid SCHEMBL8841246 | 0.84 | FOLH1 (0.59) | MMECPA1FOLH1ADRA1ACPB1 | |
| SCHEMBL270456 | 0.84 | FOLH1 (0.67) | MMECPA1FOLH1CPB1CPA3 | |
| SCHEMBL276879 | 0.84 | SLC1A3 (0.73) | MMESLC1A3SLC1A2CPA1ADRA1A | |
| SCHEMBL10000266 | 0.83 | MME (0.55) | MMESLC1A3SLC1A2CPA1CACNA2D1 | |
| SCHEMBL129650 | 0.83 | FOLH1 (0.48) | MMECPA1FOLH1CPB1CPA3 | |
| SCHEMBL25762254 | 0.83 | SLC1A3 (0.54) | MMESLC1A3SLC1A2CPA1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430735-A | Catalyst component for propylene polymerization, preparation method thereof, catalyst and application | 中国石油化工股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-109053936-B | Preparation method of polyvinyl butyral resin | 吉林吉诺树脂科技有限公司 | 2020-07-07 | — | — | CN | claimed |
| US-20030225161-A1 | GABA and L-glutamic acid analogs for antiseizure treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | claimed |
| US-5683845-A | SMALL POLYTETRAFLUOROETHYLENE PARTICLES ON SURFACE OF TONER, POLYESTER BINDER | KAO CORPORATION (JP) | 1997-11-04 | — | — | US | claimed |
| EP-0460665-B1 | Toner composition | KAO CORP (JP) | 1997-09-03 | — | — | EP | claimed |
| EP-0641330-A4 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT. | UNIV NORTHWESTERN (US) | 1997-05-28 | — | — | EP | claimed |
| US-5424161-A | Containing polyester resin | KAO CORPORATION (JP) | 1995-06-13 | — | — | US | claimed |
| EP-0641330-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0379288-B1 | Process and intermediates for isopropyl 3S-amino-2R-hydroxyalkanoates | PFIZER (US) | 1993-12-22 | — | — | EP | claimed |
| WO-1993023383-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0460665-A1 | Toner composition | KAO CORPORATION (JP) | 1991-12-11 | — | — | EP | claimed |
| US-5015724-A | Condensation of dialcohol with diacid to form a modified polymer as a developer for electrography | KAO CORPORATION (JP) | 1991-05-14 | — | — | US | claimed |
| EP-4749368-A1 | MAGNETIC ONE-COMPONENT TONER AND IMAGE FORMING APPARATUS USING THE SAME | KYOCERA Document Solutions Inc. (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4745672-A1 | MAGNETIC CARRIER AND TWO COMPONENT DEVELOPER CONTAINING THE SAME, AND METHOD FOR PRODUCING MAGNETIC CARRIER | KYOCERA Document Solutions Inc. (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-4745671-A1 | ONE-COMPONENT TONER AND IMAGE FORMING APPARATUS USING THE SAME | KYOCERA Document Solutions Inc. (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260133515-A1 | MAGNETIC ONE-COMPONENT TONER AND IMAGE FORMING APPARATUS USING THE SAME | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-4771038-A | Hydroxamic acids | ICI AMERICAS INC. (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0276436-A1 | Phosphinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-08-03 | — | — | EP | disclosed |
| CN-87101164-A | PHOSPHINIC ACID DERIVATIVES | — | 1988-06-29 | — | — | CN | disclosed |
| EP-0231081-A2 | Hydroxamic acids | ICI AMERICAS INC. (US) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260133515-A1 | MAGNETIC ONE-COMPONENT TONER AND IMAGE FORMING APPARATUS USING THE SAME | TAF1, GLRA1, TGFBR1 | MME 3706/4885SLC1A3 2845/4885SLC1A2 2574/4885 |
| US-20030225161-A1 | GABA and L-glutamic acid analogs for antiseizure treatment | GABRB1, GABRE, GABRB2 | MME 2932/4885SLC1A3 52/4885SLC1A2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.